Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezetimibe + fenofibrate (Hyundai Pharmaceutical Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Hyundai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HDDO-17561/HDDO-17562 refers to the loose combination of ezetimibe and fenofibrate, developed by Hyundai Pharmaceutical for the treatment of hyperlipidemia. Ezetimibe is a selective cholesterol absorption inhibitor that acts at the brush border of the small intestine, while fenofibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα) to modulate lipid metabolism. This combination is typically used to lower LDL cholesterol and triglycerides while increasing HDL cholesterol. Hyundai Pharmaceutical conducted Phase 1 trials to compare the pharmacokinetics and safety of this loose combination against their fixed-dose combination (FDC) formulation, HDDO-1756.
- Other names
- ezetimibe + fenofibrate
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on ezetimibe + fenofibrate (Hyundai Pharmaceutical Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezetimibe + fenofibrate (Hyundai Pharmaceutical Co., Ltd.).